Khattar Jack A.
Insider CIK 1539937 · SUPN President, CEO, Director · CGTX Director · SUPN President, CEO, Director · SCPH Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-10-30 | 2026-11-02 | 400,000 | — | $0 | 400,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 29,849 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 12,642 | $46.57 | $588.7K | 1,258,351 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 29,849 | — | $0 | 1,270,993 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 29,849 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 12,642 | $46.57 | $588.7K | 1,258,351 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 29,849 | — | $0 | 1,270,993 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 29,849 | — | $0 | 29,849 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 29,849 | — | $0 | 29,849 | SEC↗ |
| CGTX COGNITION THERAPEUTICS INC | A Award | 2026-06-17 | 2026-06-22 | 25,000 | — | $0 | 73,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-13 | 2026-03-16 | 24,138 | $50.09 | $1.21M | 968,962 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2026-03-13 | 2026-03-16 | 12,500 | — | $0 | 1,241,144 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2026-03-13 | 2026-03-16 | 12,500 | — | $0 | 993,100 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-13 | 2026-03-16 | 10,742 | $51.00 | $547.8K | 958,220 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-13 | 2026-03-16 | 120 | $51.75 | $6.2K | 958,100 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-06 | 2026-03-10 | 38,640 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-03-06 | 2026-03-10 | 16,574 | $54.73 | $907.1K | 1,228,644 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-06 | 2026-03-10 | 38,640 | — | $0 | 1,245,218 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-28 | 2026-03-03 | 38,640 | — | $0 | 38,640 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 341,610 | — | $0 | 341,610 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-10-09 | 2025-10-10 | 81,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-10-09 | 2025-10-10 | 1,529 | $51.46 | $78.7K | 1,206,578 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-10-09 | 2025-10-10 | 58,371 | $50.55 | $2.95M | 1,208,107 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-10-09 | 2025-10-10 | 81,250 | $25.30 | $2.06M | 1,266,478 | SEC↗ |
| SCPH scPharmaceuticals Inc. | D To issuer deriv | 2025-10-07 | 2025-10-07 | 30,000 | — | $0 | 0 | SEC↗ |
| SCPH scPharmaceuticals Inc. | D To issuer deriv | 2025-10-07 | 2025-10-07 | 6,124 | — | $0 | 0 | SEC↗ |
| SCPH scPharmaceuticals Inc. | D To issuer deriv | 2025-10-07 | 2025-10-07 | 16,300 | — | $0 | 0 | SEC↗ |
| SCPH scPharmaceuticals Inc. | D To issuer deriv | 2025-10-07 | 2025-10-07 | 19,750 | — | $0 | 0 | SEC↗ |
| SCPH scPharmaceuticals Inc. | U Tender | 2025-10-07 | 2025-10-07 | 5,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-10-02 | 2025-10-03 | 2,267 | — | $0 | 81,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-10-02 | 2025-10-03 | 19,320 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-10-02 | 2025-10-03 | 20,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-10-02 | 2025-10-03 | 1,904 | $48.06 | $91.5K | 1,161,233 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-10-02 | 2025-10-03 | 2,267 | $25.30 | $57.4K | 1,163,137 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-10-02 | 2025-10-03 | 20,000 | — | $0 | 1,181,233 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-10-02 | 2025-10-03 | 7,796 | $46.21 | $360.3K | 1,173,437 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-10-02 | 2025-10-03 | 7,529 | $46.21 | $347.9K | 1,185,228 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-10-02 | 2025-10-03 | 19,320 | — | $0 | 1,192,757 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-10-01 | 2025-10-02 | 53,785 | — | $0 | 83,517 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-10-01 | 2025-10-02 | 40,173 | $48.07 | $1.93M | 1,160,870 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-10-01 | 2025-10-02 | 53,785 | $25.30 | $1.36M | 1,201,043 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-09-30 | 2025-10-01 | 11,510 | — | $0 | 137,302 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-09-30 | 2025-10-01 | 8,588 | $48.25 | $414.4K | 1,147,258 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-09-30 | 2025-10-01 | 11,510 | $25.30 | $291.2K | 1,155,846 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-09-29 | 2025-09-30 | 13,688 | — | $0 | 148,812 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-09-29 | 2025-09-30 | 10,235 | $48.02 | $491.5K | 1,144,336 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-09-29 | 2025-09-30 | 13,688 | $25.30 | $346.3K | 1,154,571 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-09-23 | 2025-09-24 | 47,940 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-09-23 | 2025-09-24 | 47,940 | $12.98 | $622.3K | 1,170,396 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-09-23 | 2025-09-24 | 29,513 | $47.23 | $1.39M | 1,140,883 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-09-22 | 2025-09-23 | 27,060 | — | $0 | 47,940 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-09-22 | 2025-09-23 | 16,587 | $47.02 | $779.9K | 1,122,456 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-09-22 | 2025-09-23 | 27,060 | $12.98 | $351.2K | 1,139,043 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-09-10 | 2025-09-12 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-09-10 | 2025-09-12 | 19,320 | — | $0 | 19,320 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-09-08 | 2025-09-09 | 8,074 | — | $0 | 162,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-09-08 | 2025-09-09 | 8,074 | $25.30 | $204.3K | 1,118,305 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-09-08 | 2025-09-09 | 6,322 | $46.29 | $292.6K | 1,111,983 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-09-05 | 2025-09-08 | 73,176 | — | $0 | 170,574 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-09-05 | 2025-09-08 | 55,578 | $46.01 | $2.56M | 1,110,231 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-09-05 | 2025-09-08 | 73,176 | $25.30 | $1.85M | 1,165,809 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-28 | 2025-08-29 | 38,779 | — | $0 | 75,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-28 | 2025-08-29 | 24,150 | $45.12 | $1.09M | 1,092,633 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-28 | 2025-08-29 | 38,779 | $12.98 | $503.4K | 1,116,783 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-27 | 2025-08-29 | 17,195 | — | $0 | 113,779 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-27 | 2025-08-29 | 17,195 | $12.98 | $223.2K | 1,088,654 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-27 | 2025-08-29 | 10,650 | $45.05 | $479.8K | 1,078,004 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-25 | 2025-08-27 | 1,611 | — | $0 | 130,974 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-25 | 2025-08-27 | 1,611 | $12.98 | $20.9K | 1,072,459 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-25 | 2025-08-27 | 1,000 | $45.00 | $45.0K | 1,071,459 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-22 | 2025-08-26 | 2,415 | — | $0 | 132,585 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-22 | 2025-08-26 | 1,500 | $45.00 | $67.5K | 1,070,848 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-22 | 2025-08-26 | 2,415 | $12.98 | $31.3K | 1,072,348 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-06 | 2025-08-08 | 60,000 | — | $0 | 135,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-06 | 2025-08-08 | 60,000 | — | $0 | 195,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-06 | 2025-08-08 | 81,250 | — | $0 | 243,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-06 | 2025-08-08 | 38,500 | $40.24 | $1.55M | 1,030,183 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-06 | 2025-08-08 | 38,000 | $42.00 | $1.60M | 1,052,183 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-06 | 2025-08-08 | 81,250 | $25.30 | $2.06M | 1,133,433 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-06 | 2025-08-08 | 63,500 | $43.12 | $2.74M | 1,069,933 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-06 | 2025-08-08 | 60,000 | $12.98 | $778.8K | 1,090,183 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-06 | 2025-08-08 | 60,000 | $12.98 | $778.8K | 1,068,683 | SEC↗ |
| CGTX COGNITION THERAPEUTICS INC | A Award | 2025-06-18 | 2025-06-23 | 34,000 | — | $0 | 48,500 | SEC↗ |
| SCPH scPharmaceuticals Inc. | A Award deriv | 2025-06-03 | 2025-06-05 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2025-04-02 | 2025-04-03 | 16,850 | — | $0 | 1,005,600 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2025-04-02 | 2025-04-03 | 16,850 | — | $0 | 1,008,683 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-03-10 | 2025-03-11 | 35,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-10 | 2025-03-11 | 16,805 | $32.06 | $538.8K | 991,833 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-03-10 | 2025-03-11 | 35,000 | — | $0 | 1,008,638 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-03-07 | 2025-03-07 | 38,640 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-07 | 2025-03-07 | 18,581 | $39.11 | $726.7K | 973,638 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-03-07 | 2025-03-07 | 38,640 | — | $0 | 992,219 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-28 | 2025-03-04 | 35,000 | — | $0 | 35,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-20 | 2025-02-21 | 331,660 | — | $0 | 331,660 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-17 | 2025-02-19 | 38,640 | — | $0 | 38,640 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-12-27 | 2024-12-30 | 38,640 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-12-27 | 2024-12-30 | 14,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-12-27 | 2024-12-30 | 14,000 | — | $0 | 960,245 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-12-27 | 2024-12-30 | 38,640 | — | $0 | 964,812 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-12-27 | 2024-12-30 | 18,567 | $35.59 | $660.8K | 946,245 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-12-27 | 2024-12-30 | 6,666 | $35.59 | $237.2K | 953,579 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-12-23 | 2024-12-26 | 38,640 | — | $0 | 38,640 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-12-23 | 2024-12-26 | 14,000 | — | $0 | 14,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-11-08 | 2024-11-12 | 125,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-11-08 | 2024-11-12 | 125,000 | $9.13 | $1.14M | 1,051,172 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-11-08 | 2024-11-12 | 125,000 | $36.29 | $4.54M | 926,172 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-11-07 | 2024-11-08 | 125,000 | — | $0 | 125,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-11-07 | 2024-11-08 | 125,000 | $9.13 | $1.14M | 1,051,172 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-11-07 | 2024-11-08 | 125,000 | $36.68 | $4.58M | 926,172 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-09-03 | 2024-09-03 | 21,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-09-03 | 2024-09-03 | 10,045 | $34.90 | $350.6K | 926,172 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-09-03 | 2024-09-03 | 21,000 | — | $0 | 936,217 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-08-27 | 2024-08-27 | 21,000 | — | $0 | 21,000 | SEC↗ |
| SCPH scPharmaceuticals Inc. | A Award deriv | 2024-06-11 | 2024-06-13 | 19,750 | — | $0 | 19,750 | SEC↗ |
| CGTX COGNITION THERAPEUTICS INC | A Award deriv | 2024-06-07 | 2024-06-11 | 8,500 | — | $0 | 8,500 | SEC↗ |
| CGTX COGNITION THERAPEUTICS INC | A Award | 2024-06-07 | 2024-06-11 | 8,500 | — | $0 | 14,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-02-28 | 2024-02-29 | 35,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-28 | 2024-02-29 | 16,788 | $27.94 | $469.1K | 915,217 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-02-28 | 2024-02-29 | 35,000 | — | $0 | 932,005 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 322,000 | — | $0 | 322,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 35,000 | — | $0 | 35,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2024-02-12 | 2024-02-22 | 16,500 | — | $0 | 1,022,450 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2024-02-12 | 2024-02-22 | 16,500 | — | $0 | 897,005 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-12-22 | 2023-12-26 | 25,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-12-22 | 2023-12-26 | 25,000 | — | $0 | 892,463 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-12-22 | 2023-12-26 | 11,958 | $27.66 | $330.8K | 880,505 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-12-14 | 2023-12-18 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-09-07 | 2023-09-07 | 35,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-09-07 | 2023-09-07 | 35,000 | — | $0 | 884,267 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-09-07 | 2023-09-07 | 16,804 | $32.10 | $539.4K | 867,463 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-08-23 | 2023-08-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| CGTX COGNITION THERAPEUTICS INC | A Award deriv | 2023-06-09 | 2023-06-13 | 6,000 | — | $0 | 6,000 | SEC↗ |
| CGTX COGNITION THERAPEUTICS INC | A Award | 2023-06-09 | 2023-06-13 | 6,000 | — | $0 | 6,000 | SEC↗ |
| SCPH scPharmaceuticals Inc. | A Award deriv | 2023-06-06 | 2023-06-08 | 17,300 | — | $0 | 17,300 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-05-11 | 2023-05-12 | 31,250 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-05-11 | 2023-05-12 | 31,250 | — | $0 | 864,272 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-05-11 | 2023-05-12 | 15,005 | $36.47 | $547.2K | 849,267 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-05-04 | 2023-05-08 | 31,250 | — | $0 | 31,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-03-14 | 2023-04-10 | 20,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-03-14 | 2023-04-10 | 20,000 | — | $0 | 833,022 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 280,000 | — | $0 | 280,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-16 | 2023-02-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2023-02-15 | 2023-02-16 | 8,750 | — | $0 | 1,038,950 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2023-02-15 | 2023-02-16 | 8,750 | — | $0 | 813,022 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-02-03 | 2023-02-06 | 330 | — | $0 | 25,037 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-02-03 | 2023-02-06 | 200 | $42.02 | $8.4K | 804,272 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-02-03 | 2023-02-06 | 330 | $9.56 | $3.2K | 804,472 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-02-02 | 2023-02-06 | 22,515 | — | $0 | 25,367 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-02-02 | 2023-02-06 | 13,532 | $42.06 | $569.2K | 804,142 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-02-02 | 2023-02-06 | 22,515 | $9.56 | $215.2K | 817,674 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-02-01 | 2023-02-03 | 498 | — | $0 | 47,882 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-02-01 | 2023-02-03 | 300 | $42.01 | $12.6K | 795,159 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-02-01 | 2023-02-03 | 498 | $9.56 | $4.8K | 795,459 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-01-31 | 2023-02-02 | 1,620 | — | $0 | 48,380 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-01-31 | 2023-02-02 | 1,620 | $9.56 | $15.5K | 795,937 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-01-31 | 2023-02-02 | 976 | $42.01 | $41.0K | 794,961 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-01-18 | 2023-01-20 | 8,080 | — | $0 | 50,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-01-18 | 2023-01-20 | 8,080 | $9.56 | $77.2K | 799,253 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-01-18 | 2023-01-20 | 4,936 | $40.40 | $199.4K | 794,317 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-01-17 | 2023-01-19 | 41,920 | — | $0 | 58,080 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-01-17 | 2023-01-19 | 25,446 | $40.03 | $1.02M | 791,173 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-01-17 | 2023-01-19 | 41,920 | $9.56 | $400.8K | 816,619 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-12-21 | 2022-12-22 | 11,354 | $38.14 | $433.0K | 814,699 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-12-21 | 2022-12-22 | 18,472 | $9.56 | $176.6K | 826,053 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2022-12-21 | 2022-12-22 | 15,625 | — | $0 | 807,581 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-12-20 | 2022-12-22 | 18,472 | — | $0 | 100,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-12-20 | 2022-12-22 | 6,528 | — | $0 | 118,472 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-12-20 | 2022-12-22 | 6,528 | $9.56 | $62.4K | 795,962 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-12-20 | 2022-12-22 | 4,006 | $38.02 | $152.3K | 791,956 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-11-25 | 2022-11-28 | 17,794 | — | $0 | 125,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-11-25 | 2022-11-28 | 11,135 | $35.18 | $391.7K | 789,434 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-11-25 | 2022-11-28 | 17,794 | $9.56 | $170.1K | 800,569 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-11-23 | 2022-11-28 | 3,616 | — | $0 | 142,794 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-11-23 | 2022-11-28 | 3,616 | $9.56 | $34.6K | 785,034 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-11-23 | 2022-11-28 | 2,259 | $35.05 | $79.2K | 782,775 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-11-22 | 2022-11-23 | 959 | — | $0 | 146,410 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-11-22 | 2022-11-23 | 600 | $35.00 | $21.0K | 781,418 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-11-22 | 2022-11-23 | 959 | $9.56 | $9.2K | 782,018 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-11-21 | 2022-11-22 | 848 | — | $0 | 147,369 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-11-21 | 2022-11-22 | 531 | $35.01 | $18.6K | 781,059 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-11-21 | 2022-11-22 | 848 | $9.56 | $8.1K | 781,590 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-11-15 | 2022-11-17 | 1,783 | — | $0 | 148,217 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-11-15 | 2022-11-17 | 1,783 | $9.56 | $17.0K | 781,857 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-11-15 | 2022-11-17 | 1,115 | $35.00 | $39.0K | 780,742 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-09-14 | 2022-09-15 | 5,895 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-09-14 | 2022-09-15 | 5,895 | — | $0 | 781,454 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-09-14 | 2022-09-15 | 1,380 | $33.75 | $46.6K | 780,074 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-08-16 | 2022-08-18 | 39,530 | — | $0 | 5,895 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-08-16 | 2022-08-18 | 14,690 | $34.01 | $499.6K | 775,559 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-16 | 2022-08-18 | 9,182 | $34.01 | $312.3K | 790,249 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-16 | 2022-08-18 | 39,530 | — | $0 | 799,431 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-08-15 | 2022-08-17 | 46,575 | — | $0 | 45,425 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-15 | 2022-08-17 | 46,575 | — | $0 | 788,016 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-15 | 2022-08-17 | 10,813 | $34.03 | $368.0K | 777,203 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-08-15 | 2022-08-17 | 17,302 | $34.03 | $588.8K | 759,901 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-08-10 | 2022-08-11 | 44,900 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-08-10 | 2022-08-11 | 28,437 | $31.22 | $887.8K | 741,441 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-10 | 2022-08-11 | 44,900 | — | $0 | 769,878 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-08-09 | 2022-08-10 | 63,100 | — | $0 | 44,900 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-08-09 | 2022-08-10 | 39,431 | $31.15 | $1.23M | 724,978 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-09 | 2022-08-10 | 63,100 | — | $0 | 764,409 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-08-08 | 2022-08-09 | 192,000 | — | $0 | 108,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-08-08 | 2022-08-09 | 107,875 | $31.40 | $3.39M | 711,341 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2022-08-08 | 2022-08-09 | 10,032 | $32.11 | $322.1K | 701,309 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-08-08 | 2022-08-09 | 192,000 | — | $0 | 819,216 | SEC↗ |
| SCPH scPharmaceuticals Inc. | A Award deriv | 2022-06-14 | 2022-06-15 | 16,300 | — | $0 | 16,300 | SEC↗ |
| CGTX COGNITION THERAPEUTICS INC | A Award deriv | 2022-06-10 | 2022-06-13 | 8,335 | — | $0 | 8,335 | SEC↗ |
| CGTX COGNITION THERAPEUTICS INC | A Award deriv | 2022-06-10 | 2022-06-23 | 8,335 | — | $0 | 8,335 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2022-03-18 | 2022-03-23 | 10,750 | — | $0 | 1,047,700 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2022-03-18 | 2022-03-23 | 10,750 | — | $0 | 627,216 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2022-03-14 | 2023-01-13 | 40,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2022-03-14 | 2023-01-13 | 40,000 | — | $0 | 556,466 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2022-03-14 | 2023-01-13 | 20,000 | — | $0 | 576,466 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2022-03-14 | 2022-03-17 | 60,000 | — | $0 | 616,466 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 250,000 | — | $0 | 250,000 | SEC↗ |
| SCPH scPharmaceuticals Inc. | P Buy | 2021-12-03 | 2021-12-06 | 5,000 | $3.91 | $19.6K | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-07-30 | 2023-01-13 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2021-07-30 | 2021-07-30 | 40,000 | — | $0 | 556,466 | SEC↗ |
| SCPH scPharmaceuticals Inc. | A Award deriv | 2021-06-08 | 2021-06-10 | 16,300 | — | $0 | 16,300 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2021-03-26 | 2021-03-30 | 10,000 | — | $0 | 516,466 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2021-03-26 | 2021-03-30 | 10,000 | — | $0 | 1,058,450 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-02-19 | 2021-02-23 | 200,000 | — | $0 | 200,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2020-07-27 | 2020-07-28 | 15,625 | — | $0 | 506,466 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2020-07-10 | 2020-07-13 | 15,625 | — | $0 | 490,841 | SEC↗ |
| SCPH scPharmaceuticals Inc. | A Award deriv | 2020-06-09 | 2020-06-11 | 6,124 | — | $0 | 6,124 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2020-03-23 | 2020-03-23 | 13,000 | — | $0 | 475,216 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | J Other | 2020-03-23 | 2020-03-23 | 13,000 | — | $0 | 1,068,450 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2020-02-21 | 2020-02-25 | 281,250 | — | $0 | 281,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | G Gift | 2019-12-26 | 2019-12-27 | 1,100 | — | $0 | 4,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | G Gift | 2019-12-26 | 2019-12-27 | 1,100 | — | $0 | 462,941 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | G Gift | 2019-12-26 | 2019-12-27 | 1,100 | — | $0 | 464,041 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | G Gift | 2019-12-26 | 2019-12-27 | 1,100 | — | $0 | 461,841 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | P Buy | 2019-08-23 | 2019-08-27 | 7,200 | $26.39 | $190.0K | 465,141 | SEC↗ |
| SCPH scPharmaceuticals Inc. | A Award deriv | 2019-06-18 | 2019-06-20 | 6,124 | — | $0 | 6,124 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2019-03-20 | 2019-03-20 | 4,500 | — | $0 | 457,565 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2019-03-20 | 2019-03-20 | 4,500 | — | $0 | 1,081,450 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2019-02-22 | 2019-02-26 | 300,000 | — | $0 | 300,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2019-01-15 | 2019-01-17 | 400 | — | $0 | 453,065 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2019-01-15 | 2019-01-17 | 400 | — | $0 | 2,900 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2019-01-15 | 2019-01-17 | 400 | — | $0 | 453,465 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2019-01-15 | 2019-01-17 | 400 | — | $0 | 453,865 | SEC↗ |
| SCPH scPharmaceuticals Inc. | A Award deriv | 2018-06-19 | 2018-06-21 | 6,124 | — | $0 | 6,124 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2018-04-03 | 2018-04-04 | 3,800 | — | $0 | 1,085,950 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2018-04-03 | 2018-04-04 | 3,800 | — | $0 | 453,744 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2018-02-14 | 2018-02-16 | 250,000 | — | $0 | 250,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2017-12-22 | 2017-12-26 | 250 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2017-12-22 | 2017-12-26 | 250 | — | $0 | 449,654 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2017-12-22 | 2017-12-26 | 250 | — | $0 | 450,154 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2017-12-22 | 2017-12-26 | 250 | — | $0 | 449,904 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2017-04-03 | 2017-04-04 | 4,250 | — | $0 | 449,909 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2017-04-03 | 2017-04-04 | 4,250 | — | $0 | 1,089,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2017-02-24 | 2017-02-27 | 325,000 | — | $0 | 325,000 | SEC↗ |
| SUPN TESARO, Inc. | J Other | 2016-03-29 | 2016-03-30 | 7,000 | — | $0 | 1,094,000 | SEC↗ |
| SUPN TESARO, Inc. | J Other | 2016-03-29 | 2016-03-30 | 7,000 | — | $0 | 444,124 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2016-03-29 | 2016-03-30 | 7,000 | — | $0 | 444,124 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2016-03-29 | 2016-03-30 | 7,000 | — | $0 | 1,094,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2016-03-01 | 2016-03-03 | 255,000 | — | $0 | 255,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2015-12-28 | 2015-12-30 | 1,000 | — | $0 | 436,434 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2015-12-28 | 2015-12-30 | 1,000 | — | $0 | 437,434 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2015-12-28 | 2015-12-30 | 1,000 | — | $0 | 438,434 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2015-12-28 | 2015-12-30 | 1,000 | — | $0 | 2,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2015-03-19 | 2015-03-20 | 6,000 | — | $0 | 1,101,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2015-03-19 | 2015-03-20 | 6,000 | — | $0 | 438,573 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2015-03-03 | 2015-03-05 | 250,000 | — | $0 | 250,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2014-08-25 | 2014-08-29 | 1,250 | — | $0 | 431,436 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2014-08-25 | 2014-08-29 | 1,250 | — | $0 | 433,936 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2014-08-25 | 2014-08-29 | 1,250 | — | $0 | 1,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | G Gift | 2014-08-25 | 2014-08-29 | 1,250 | — | $0 | 432,686 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2014-03-28 | 2014-04-01 | 7,000 | — | $0 | 1,107,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2014-03-28 | 2014-04-01 | 7,000 | — | $0 | 433,689 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2014-01-23 | 2014-04-01 | 150,000 | — | $0 | 150,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2014-01-23 | 2014-01-23 | 150,000 | — | $0 | 150,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2013-04-04 | 2014-04-01 | 11,000 | — | $0 | 426,689 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | J Other | 2013-04-04 | 2014-04-01 | 11,000 | — | $0 | 1,114,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | P Buy | 2013-03-15 | 2013-03-19 | 10,000 | $6.15 | $61.5K | 412,058 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2013-02-05 | 2013-02-07 | 392,000 | — | $0 | 392,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2013-02-05 | 2013-03-19 | 300,000 | — | $0 | 300,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2013-02-05 | 2013-03-19 | 92,000 | — | $0 | 92,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | P Buy | 2012-05-04 | 2012-05-07 | 5,000 | $5.00 | $25.0K | 402,058 | SEC↗ |